Skip to main content

Table 1 Statistics of BC patients in New Hampshire 2010–2016

From: Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016

Variable ODX Not Given (n = 4118) ODX Given (n = 1512) Total (n = 5630) P-Value
Patient Age at Diagnosis (Years) < 0.01**
 < 50 7870 (18.9%) 317 (21.0%) 1097 (19.5%)  
 50–59 974 (23.7%) 447 (29.6%) 1421 (25.2%)  
 60–69 1166 (28.3%) 518 (34.3%) 1684 (29.9%)  
 > 69 1198 (29.1%) 230 (15.2%) 1428 (25.4%)  
Marital Status < 0.01**
 Single 1620 (39.3%) 464 (30.7%) 2084 (37.0%)  
 Married 2391 (58.1%) 1010 (66.8%) 3401 (60.4%)  
 Unknown 107 (2.6%) 38 (2.5%) 145 (2.6%)  
Payer < 0.01**
 Self-Pay 86 (2.1%) 18 (1.2%) 104 (1.8%)  
 Public 1901 (46.2%) 516 (34.1%) 2417 (42.9%)  
 Private 1659 (40.3%) 790 (52.2%) 2449 (43.5%)  
 Unknown 472 (11.5%) 188 (12.4%) 660 (11.7%)  
Year of Diagnosis 0.14
 2010 526 (12.8%) 172 (11.4%) 698 (12.4%)  
 2011 577 (14.0%) 198 (13.1%) 775 (13.8%)  
 2012 528 (12.8%) 185 (12.2%) 713 (12.7%)  
 2013 580 (14.1%) 189 (12.5%) 769 (13.7%)  
 2014 613 (14.9%) 242 (16.0%) 855 (15.2%)  
 2015 668 (16.2%) 269 (17.8%) 937 (16.6%)  
 2016 626 (15.2%) 257 (17.0%) 883 (15.7%)  
Tumor Size (mm) < 0.01**
 0.1–19 2390 (58.0%) 1023 (67.7%) 3413 (60.6%)  
 20–39 981 (23.8%) 417 (27.6%) 1398 (24.8%)  
 > 40 627 (15.2%) 64 (4.2%) 691 (12.3%)  
 Unknown 120 (2.9%) 8 (0.5%) 128 (2.3%)  
Tumor Grade < 0.01**
 I 854 (20.7%) 398 (26.3%) 1252 (22.2%)  
 II 1719 (41.7%) 844 (55.8%) 2563 (45.5%)  
 III / IV 1403 (34.1%) 265 (17.5%) 1668 (29.6%)  
 Unknown 142 (3.4%) 5 (0.3%) 147 (2.6%)  
LN Status < 0.01**
 Negative 2289 (55.6%) 1196 (79.1%) 3485 (61.9%)  
 Positive 1257 (30.5%) 284 (18.8%) 1541 (27.4%)  
 Unknown 572 (13.9%) 32 (2.1%) 604 (10.7%)  
ER/PR/HER2 Status < 0.01**
 HR+/HER2- 2663 (64.7%) 1446 (95.6%) 4109 (73.0%)  
 Other 1270 (30.8%) 41 (2.7%) 1311 (23.3%)  
 Unknown 185 (4.5%) 25 (2.5%) 210 (3.7%)  
Clinical Stage < 0.01**
 1 2152 (52.3%) 1034 (68.4%) 3186 (56.6%)  
 2 1166 (28.3%) 453 (30.0%) 1619 (28.8%)  
 3 / 4 800 (19.4%) 25 (1.7%) 825 (14.7%)  
ODX Eligiblea 1472 (35.7%) 1132 (74.9%) 2604 (46.3%) < 0.01**
MD Gender 0.34
 Female 2212 (53.7%) 790 (52.2%) 3002 (53.3%)  
 Male 1906 (46.3%) 722 (47.8%) 2628 (46.7%)  
MD Clinical Experience (Years) 0.08
 < 10 169 (4.1%) 58 (3.8%) 227 (4.0%)  
 10–19 1774 (43.1%) 604 (39.9%) 2378 (42.2%)  
 20–29 1254 (30.5%) 511 (33.8%) 1765 (31.3%)  
 > 29 921 (22.4%) 339 (22.4%) 1260 (22.4%)  
Surgical Specialty 0.72
 General Surgeon 3582 (87.0%) 1309 (86.6%) 4891 (86.9%)  
 Surgical Oncologist 536 (13.0%) 203 (13.4%) 739 (13.1%)  
  1. P-values were calculated using chi-square test for categorical variables
  2. * significant at the 0.05 level
  3. ** significant at the 0.01 level
  4. aODX eligible patients are defined as stage 1 or 2, LN negative, and HR+/HER2-